Leveraging EA8191 to Assess AI-Augmented EHR Abstraction

Active, not recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

April 30, 2026

Conditions
Prostate Cancer
Interventions
OTHER

Chart review

Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mendel AI

INDUSTRY

lead

University of Pennsylvania

OTHER